ClinicalTrials.gg
CompletedNCT03679884Updated Mar 2, 2022Results posted

Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

A Phase 3 interventional study of Daridorexant 10 mg and Daridorexant 25 mg in Insomnia Disorder, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 106 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-02.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
804
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders — 6 open to participants now, 6 under way, none of them phase 3. daridorexant · Sleep Initiation and Maintenance Disorders.

Enrollment
4th of 16
804 · median 165
Started
2018
with 2 others
Phase 3
5 of 16
none open now
Registered
6th of 16
by date
Lead sponsor
8 of 16
Idorsia Pharmaceuticals Ltd.

Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, this one is the 4th largest by enrollment, is one of 3 that started in 2018, is one of 5 in phase 3, and was the 6th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

6 of the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About daridorexant

daridorexant: first FDA approval 2022 (QUVIVIQ), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

Study to assess the long term safety and tolerability of daridorexant in adult and elderly subjects suffering from difficulties to sleep

03

Conditions studied

  • Insomnia Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to any study-mandated procedure (Visit 1).
  • Having completed the DB study treatment and the run-out period of ID-078A301 (NCT03545191) or ID-078A302 (NCT03575104).
  • For woman of , the following is required:

    • Negative urine pregnancy test (EOT of ID-078A301 or ID-078A302 studies)
    • Agreement to use the scheme as required by the protocol from Visit 1 up to at least 30 days after EODBT.

Exclusion criteria

Exclusion Criteria:

  • Unstable medical condition, significant medical disorder or acute illness, C-SSRS©, , hematology or biochemistry test results in ID-078A301 and ID-078A302, which in the opinion of the investigator could affect the subject's safety or interfere with the study assessments (Visit 1).
  • For female subjects: lactating or planning to become pregnant during the duration of the study (Visit 1).
  • Positive urine drug test (for benzodiazepines, barbiturates, cannabinoids, opiates, amphetamines, or cocaine) or presence of alcohol in exhaled breath as detected by breathalyzer test (EOT of ID-078A301 or ID-078A302 studies if same day as Visit 1 or Visit 1 if within 7 days after EOT).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
804 participants (actual)

Study arms

  • Experimental
    Daridorexant 10 mg

    Film-coated tablets administered orally, once daily in the evening

    Drug: Daridorexant 10 mg

  • Experimental
    Daridorexant 25 mg

    Film-coated tablets administered orally, once daily in the evening

    Drug: Daridorexant 25 mg

  • Experimental
    Daridorexant 50 mg

    Film-coated tablets administered orally, once daily in the evening

    Drug: Daridorexant 50 mg

  • Placebo comparator
    Placebo

    Film-coated tablets administered orally, once daily in the evening

    Drug: Placebo

  • Experimental
    Ex-Placebo Daridorexant 25 mg

    Film-coated tablets administered orally, once daily in the evening

    Drug: Daridorexant 25 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Total no. of Subjects With at Least One TEAE

    The primary objective of the study was to assess the long-term safety and tolerability of 10, 25 and 50 mg daridorexant. The total no. of subjects with at least one TEAE is presented here; no statistical analysis was conducted. The full set of safety data is available in the Section "Adverse events".

    Time frame: TEAEs (AEs that started or worsened during the double-blind study period up to 30 days after double-blind study treatment end date) are reported. Total duration: up to 44 weeks.

07

Results

Posted Mar 2, 2022

Participant flow

Ninety-four sites in 14 countries (Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Hungary, South Korea, Poland, Spain, Sweden, Switzerland, and the US) enrolled and randomized subjects.

Participant flow — Overall Study
MilestoneDaridorexant 10 mgDaridorexant 25 mgDaridorexant 50 mgPlaceboExPlacebo/Daridorexant 25 mg
Started142268137128126
Completed99190937890
Not completed4378445036
Withdrew: Other12121278
Withdrew: Lack of efficacy1529132910
Withdrew: Death10000
Withdrew: Adverse event210966
Withdrew: Withdrawal by subject1223889
Withdrew: Lost to follow-up14203

Outcome measures

PrimaryTotal no. of Subjects With at Least One TEAE

The primary objective of the study was to assess the long-term safety and tolerability of 10, 25 and 50 mg daridorexant. The total no. of subjects with at least one TEAE is presented here; no statistical analysis was conducted. The full set of safety data is available in the Section "Adverse events".

Time frame:
TEAEs (AEs that started or worsened during the double-blind study period up to 30 days after double-blind study treatment end date) are reported. Total duration: up to 44 weeks.
Reported as:
Count of participants · Participants
Total no. of Subjects With at Least One TEAE
ParticipantsDaridorexant 10 mgDaridorexant 25 mgDaridorexant 50 mgPlaceboExPlacebo / Daridorexant 25 mg
Total no. of Subjects With at Least One TEAE53103554548

Adverse events

Collected over All treatment-emergent SAEs and AEs are reported.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Daridorexant 10 mg1/142 (0.7%)5/142 (3.5%)7/142 (4.9%)
Daridorexant 25 mg1/268 (0.4%)12/268 (4.5%)15/268 (5.6%)
Daridorexant 50 mg0/137 (0%)7/137 (5.1%)12/137 (8.8%)
Placebo0/128 (0%)2/128 (1.6%)6/128 (4.7%)
Ex-Placebo Daridorexant 25 mg0/126 (0%)4/126 (3.2%)11/126 (8.7%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventDaridorexant 10 mgDaridorexant 25 mgDaridorexant 50 mgPlaceboEx-Placebo Daridorexant 25 mg
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1420/2680/1370/1280/126
Aortic valve disease mixedCardiac disorders0/1420/2680/1370/1281/126
Chest discomfortGeneral disorders0/1420/2680/1370/1281/126
AppendicitisInfections and infestations0/1420/2680/1370/1281/126
Cerebrovascular accidentNervous system disorders1/1420/2680/1370/1281/126
Head injuryInjury, poisoning and procedural complications0/1420/2680/1371/1280/126
Subdural haematomaInjury, poisoning and procedural complications0/1420/2680/1371/1280/126
DepressionPsychiatric disorders0/1420/2680/1371/1280/126
Suicidal ideationPsychiatric disorders0/1420/2680/1371/1280/126
DiverticulitisInfections and infestations0/1422/2681/1370/1280/126
Most frequent other events
Most frequent other events
EventDaridorexant 10 mgDaridorexant 25 mgDaridorexant 50 mgPlaceboEx-Placebo Daridorexant 25 mg
NasopharyngitisInfections and infestations7/14215/26812/1376/12811/126

Baseline characteristics

These are the participants included in the FAS. The discrepancy with previous table (Participant Flow) is due to 3 subjects on FAS (2 on daridorexant 25 mg and 1 on ex-placebo/ daridorexant 25 mg) not starting DB treatment.

Age, Categorical
Age, Categorical(Participants)Daridorexant 10 mgDaridorexant 25 mgDaridorexant 50 mgPlaceboExPlacebo/Daridorexant 25 mgTotal
<=18 years000000
Between 18 and 65 years80166837070469
>=65 years62104545857335
Age, Continuous
Age, Continuous(years)Daridorexant 10 mgDaridorexant 25 mgDaridorexant 50 mgPlaceboExPlacebo/Daridorexant 25 mgTotal
Mean58.6 ± 12.857.6 ± 14.156.9 ± 13.659.2 ± 12.656.5 ± 15.557.7 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)Daridorexant 10 mgDaridorexant 25 mgDaridorexant 50 mgPlaceboExPlacebo/Daridorexant 25 mgTotal
Female103199989283575
Male3971393644229
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Daridorexant 10 mgDaridorexant 25 mgDaridorexant 50 mgPlaceboExPlacebo/Daridorexant 25 mgTotal
Black or African American619158755
American Indian or Alaska Native201003
Native Hawaiian or other Pacific Islander000101
Asian5802520
White128243121115115722
Other000202
Not permitted as per legislation/regulation100001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Daridorexant 10 mgDaridorexant 25 mgDaridorexant 50 mgPlaceboExPlacebo/Daridorexant 25 mgTotal
Hispanic or Latino63319101381
Not Hispanic or Latino135237118118114722
Unknown000000
Not permitted as per legislation/regulation100001
08

Study locations

106 sites
  • Pulmonary Associates of the Southeast/WCR
    Birmingham, Alabama 35243, United States
  • Pulmonary Associates, Pa
    Glendale, Arizona 85306, United States
  • Noble Clinical Research
    Tucson, Arizona 85704, United States
  • Preferred Research Partners, Inc
    Little Rock, Arkansas 72211, United States
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Core Healthcare Group
    Cerritos, California 90703, United States
  • Marvel Clinical Research
    Huntington Beach, California 92647, United States
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • Long Beach Clinical Trials
    Long Beach, California 90806, United States
  • Artemis Institute For Clinical Research - Riverside
    Riverside, California 92503, United States
  • Artemis institute for Clinical Research
    San Diego, California 92103, United States
  • Pacific Research Network
    San Diego, California 92103, United States
  • Artemis Institute for Clinical Research
    San Marcos, California 92078, United States
  • Santa Monica Clinical Trials
    Santa Monica, California 90404, United States
  • Empire Clinical Research
    Upland, California 91786, United States
  • Innovative Clinical Research
    Lafayette, Colorado 80026, United States
  • PAB Clinical Research
    Brandon, Florida 33511, United States
  • St. Francis Sleep Allergy and Lung Institute
    Clearwater, Florida 33765, United States
  • Clinical Research of South Florida
    Coral Gables, Florida 33134, United States
  • Fleming Island Center for Clinical Research
    Fleming Island, Florida 32003, United States
  • Research Centers of America
    Hollywood, Florida 33024, United States
  • Canvas Clinical Research, LLC
    Lake Worth, Florida 33467, United States
  • BioMed Research Institute
    Miami, Florida 33126, United States
  • Clinical Research Group of St. Petersburgh
    Saint Petersburg, Florida 33707, United States
  • Clinical Site Partners, LLC
    Winter Park, Florida 32789, United States
  • Neurotrials Research Incorporated
    Atlanta, Georgia 30342, United States
  • Sleep Practitioners, LLC
    Macon, Georgia 31210, United States
  • Saltzer Clinical Research
    Nampa, Idaho 83686, United States
  • Helene Emsellem, MD
    Chevy Chase, Maryland 20815, United States
  • Sleep Disorders Center of the Mid-Atlantic
    Glen Burnie, Maryland 21061, United States
  • Infinity Medical Research, Inc.
    North Dartmouth, Massachusetts 02747, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • Barrett Clinic
    La Vista, Nebraska 68128, United States
  • Clinical Research Center of Nevada
    Las Vegas, Nevada 89104, United States
  • Clinilabs NYC
    New York, New York 10019, United States
  • Research Carolina of Hickory
    Hickory, North Carolina 28601, United States
  • Research Carolina of Huntersville
    Huntersville, North Carolina 28078, United States
  • Coastal Carolina Healthcare
    New Bern, North Carolina 28562, United States
  • Wake Research Associates
    Raleigh, North Carolina 27604-1547, United States
  • Clinical Trials of America - NC, LLC
    Winston-Salem, North Carolina 27103, United States
  • CTI Clinical Research II
    Cincinnati, Ohio 45212, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45255, United States
  • Aventiv Research Inc.
    Dublin, Ohio 43016, United States
  • Cleveland Sleep Research Center
    Middleburg Heights, Ohio 44130, United States
  • Oregon Center for Clinical Investigations,Inc
    Salem, Oregon 97301, United States
  • Brian Abaluck LLC
    Paoli, Pennsylvania 19301, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • FutureSearch Trials of Neurology, LP
    Austin, Texas 78731, United States
  • Inquest Clinical Research
    Baytown, Texas 77521, United States
  • InSite Clinical Research
    DeSoto, Texas 75115, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Texas 32216, United States
  • Sleep Disorders Centers of the Mid-Atlantic
    Vienna, Virginia 22182, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
  • Hospital UZ Leuven_ Pneumology Department
    Leuven, 3000, Belgium
  • Acibadem City Clinic Tokuda Hospital EAD
    Sofia, 1407, Bulgaria
  • Queensway Sleep Lab Sleep Clinic (MedSleep)
    Etobicoke, M9C 5N2, Canada
  • The Medical Arts Health Research Group
    Kelowna, V1Y 3G8, Canada
  • Somni Research Inc.
    Markham, L3R 1A3, Canada
  • CRIUSMQ- CIUSSSCN, CETS (clinique du sommeil)
    Quebec, G1J 2G2, Canada
  • CANADIAN PHASE ONWARD INC. (Toronto)
    Toronto, M3J 0K2, Canada
  • MedSleep
    Toronto, M4P 1P2, Canada
  • Jodha Tishon Inc.
    Toronto, M5G1N8, Canada
  • Scan Sleep Specialists
    København, 1053, Denmark
  • Vitalmed Uniklinikka
    Helsinki, 380, Finland
  • Oivauni Oy - Kuopio
    Kuopio, 70100, Finland
  • Oivauni Oy - Tampere
    Tampere, Finland
  • Unitutkimusyksikkö, Turun Yliopisto
    Turku, Finland
  • CHU NIMES - Unité de Sommeil
    Nîmes, 30029, France
  • St Hedwig-Krankenhaus, Klinik für Schlaf- und Chronomedizin
    Berlin, 10115, Germany
  • Klinische Forschung Berlin-Mitte GmbH
    Berlin, 10117, Germany
  • emovis GmbH
    Berlin, 10629, Germany
  • Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin Kompetenzzentrum Schlafmedizin
    Berlin, 12200, Germany
  • Synexus Berlin Research Centre
    Berlin, 12627, Germany
  • Synexus Clinical Research GmbH
    Bochum, 44787, Germany
  • Klinische Forschung Dresden GmbH
    Dresden, 1069, Germany
  • Klinik imd Poliklinik fur Neurochirurgie
    Dresden, 1307, Germany
  • Synexus Clinical Research GmbH
    Frankfurt, 60313, Germany
  • Clinical Trial Center North GmbH & Co. KG
    Hamburg, 20251, Germany
  • Klinische Forschung Hamburg GmbH
    Hamburg, 20253, Germany
  • Klinische Forschung Hannover Mitte GmbH
    Hannover, 30159, Germany
  • Klinische Forschung Karlsruhe GmbH
    Karlsruhe, 76137, Germany
  • Studienzentrum Wilhelmshöhe GmbH
    Kassel, 34131, Germany
  • Synexus Leipzig Research Centre
    Leipzig, 4103, Germany
  • Zentrum für Integrative Psychiatrie (ZiP) Universität zu Lübeck
    Lübeck, 23538, Germany
  • Central Insitute of Mental Health Sleep laboratory Medical Faculty Mannheim/Heidelberg University
    Mannheim, 68159, Germany
  • Klinikum Rechts der lsar TU München Dept. of Psychiatry and Psychotherapy
    München, 81675, Germany
  • Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie der Universität am Bezirksklinikum Regensburg
    Regensburg, 93053, Germany
  • SOMNIBENE Institut für Medizinische Forschung und Schlafmedizin Schwerin GmbH
    Schwerin, 19053, Germany
  • Kinische Forschung Schwerin GmbH
    Schwerin, 19055, Germany
  • ZMS Zentrum für medizinische Studien GmbH
    Warendorf, 48231, Germany
  • Magyar Honvédség Egészségügyi Központ, Neurológiai Osztály
    Budapest, 1134, Hungary
  • Somnius Kft. SomnoCenter Szeged
    Szeged, 6725, Hungary
  • 4F Neuroimaging analysis laboratory, 56 Dalseong-ro, Jung-gu
    Daegu, 41931, Korea, Republic of
  • 2F Psychiatry Outpatient, 93, Jungbu-daero, Paldal-gu
    Suwon, 16247, Korea, Republic of
  • PI-House - Centrum Badań Klinicznych
    Gdańsk, 80-546, Poland
  • Ośrodek Medycyny Study Nurseu Instytutu Psychiatrii i Neurologii (Sleep Disorders Center)
    Warsaw, 02-957, Poland
  • EMC Instytut Medyczny SA, Przychodnia przy Łowieckiej
    Wroclaw, 50220, Poland
  • Centro Médico Teknon - Medicina del Sueño
    Barcelona, 8017, Spain
  • Hospital Universitari Vall d'Hebron - Neurophisiology Deparment - Sleep Unit
    Barcelona, 8035, Spain
  • Instituto de Investigaciones del Sueno
    Madrid, 28036, Spain

Showing the first 100 of 106 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Feb 2021, 28 months.

Results were first posted in Mar 2022, 1 year after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 28 months is above that.

Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2018
First posted
Sep 21, 2018
StartActual
Oct 9, 2018
Primary completionActual
Feb 22, 2021
CompletionActual
Feb 22, 2021
Results first posted
Mar 2, 2022
Last update
Mar 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03679884
Responsible party
Sponsor
First posted
Sep 21, 2018
Start date
Oct 9, 2018
Primary completion
Feb 22, 2021
Completion
Feb 22, 2021
Results posted
Mar 2, 2022
Last update
Mar 2, 2022

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion